Efficacy of Loratadine Compared with Fexofenadine or Placebo for the Treatment of Seasonal Allergic Rhinitis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To compare loratadine with fexofenadine and placebo in relieving symptoms of seasonal allergic rhinitis (SAR).
A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study.
Participants were aged 12 to 60 years with spring/summer SAR and total symptom severity scores (TSS) of at least 8 (maximum score 15) on six of 14 pre-baseline time-points.
Loratadine 10mg once daily, fexofenadine 60mg twice daily, or placebo for 7 days.
Main Outcome Measures and Results
The primary end-point was the reduction from baseline in am and pm reflective and instantaneous TSS at final assessment. Times to 25% and maximum reductions in am reflective TSS were also analysed. Drug administration with either loratadine or fexofenadine provided significant relief versus placebo: both agents provided similar reductions from baseline in am and pm reflective and instantaneous TSS at final assessment. Compared with fexofenadine, loratadine demonstrated a statistically greater percentage reduction in am and pm reflective TSS in four of the initial five assessments (p < 0.05 for day 1 pm, day 2 pm, and day 3 am and pm assessments), achieving significance versus fexofenadine as early as 12 hours following the first dose (day 1 pm). Median times to a 25% reduction and maximum reduction in am reflective TSS also occurred significantly earlier in patients receiving loratadine.
Compared with placebo, both loratadine and fexofenadine provided significant relief of the symptoms of SAR. At the first assessment following the first dose, however, loratadine demonstrated a significant reduction from baseline in TSS compared with fexofenadine. In addition, time-to-event analysis indicated that the reduction in symptoms occurred significantly earlier with loratadine.
- Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann Allergy Asthma Immunol 1999; 82: 296–305 CrossRef
- Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996; 17: 185–9 CrossRef
- Marshall PS, Colon EA. Effects of allergy season on mood and cognitive function. Ann Allergy 1993; 71: 251–8
- Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518 CrossRef
- Gonzalez MA, Estes KS. Pharmacokinetic overview of oral second-generation H1 antihistamines. Int J Clin Pharmacol Ther 1998; 36: 292–300
- Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55: 116–34 CrossRef
- Claritin (loratadine) prescribing information. Physicians’ Desk Reference. Montvale, NJ: Medical Economics, 2000: 2781–3
- Allegra (fexofenadine) prescribing information. Physicians’ Desk Reference. Montvale, NJ: Medical Economics, 2000: 1343–4
- Gutkowski A, Bedard PM, Del Carpio J, et al. Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1988; 81 (5 Pt 1): 902–7 CrossRef
- Del Carpio J, Kabbash L, Turenne Y, et al. Efficacy and safety of loratadine (10 mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84: 741–6 CrossRef
- Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999; 20: 193–8 CrossRef
- Bronsky E, Falliers CJ, Kaiser HB, et al. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998; 19:135–41 CrossRef
- Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30: 891–9 CrossRef
- Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther 2000; 22: 760–9 CrossRef
- Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79: 533–40 CrossRef
- Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 163–72 CrossRef
- Bedard PM, Del Carpio J, Drouin MA, et al. Onset of action of loratadine and placebo and other efficacy variables in patients with seasonal allergic rhinitis. Clin Ther 1992; 14: 269–75
- Efficacy of Loratadine Compared with Fexofenadine or Placebo for the Treatment of Seasonal Allergic Rhinitis
Clinical Drug Investigation
Volume 21, Issue 8 , pp 571-578
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Clinical Research Institute, 825 Nicollet Mall, Suite 1149, Minneapolis, Minnesota, MN 55402, USA
- 2. Allergy Research Associates, Media, Pennsylvania, USA
- 3. Atlanta Allergy & Immunology Research Foundation, Atlanta, Georgia, USA
- 4. Integrated Therapeutics Group, Inc., New Jersey, USA